Cryo-Cell International (CCEL): מחיר למכירות

Cryo-Cell International (CCEL) operates strictly within the US, leaving its business completely isolated from external sanctions and currency risks. The price-to-sales trend allows for a valuation of the company relative to its revenue, where 1.40 is recorded as the baseline value. The model relies on high-margin cryopreservation payments to create a stable cash flow, although fierce competition with state banks and laboratories is hindering expansion.

Cryo-Cell International (CCEL) develops a strictly regulated umbilical cord blood banking business by investing in highly qualified medical personnel. The ratio of market capitalization to annual revenue determines how much an investor pays per unit of the company's actual trading turnover. This metric allows one to filter out speculative noise and assess the fundamental overbought status of the asset. Analyzing the history of P/S values helps avoid entering at peaks and protects capital from a prolonged drawdown.